Nine Diagnostics was selected to present at Biotech Investor Day, a curated forum hosted by LabCentral connecting high-potential biotech and diagnostics companies with leading investors and strategic partners — including Johnson & Johnson, Pfizer, Eli Lilly, Merck, Novartis, and other top-tier life sciences organizations. Being chosen to present in this setting reflects growing interest in our approach and provided a direct opportunity to share our vision for a biomarker-agnostic, nanosensor-driven platform that uses machine learning to translate complex molecular patterns into clinically actionable insights. During the event, we highlighted our progress in building a scalable diagnostic foundation for oncology applications, including early detection and treatment response monitoring, and discussed our roadmap toward clinical validation and commercialization. Participation enabled targeted conversations with investors and senior partners from across the life sciences ecosystem — organizations that are actively shaping the future of diagnostics, precision medicine, and AI-enabled healthcare — helping expand our network for future fundraising and strategic collaboration.
Link [BioTech Investor Day]